Novartis

Selected news for the company - Novartis, collected since 10/2017. Recent stories appear in PR Newswire and pennsylvanialatinonews.com. This company shares news with Pfizer, Merck, GlaxoSmithKline, Food and Drug Administration, Biotech and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
6/15/2021 Owkin Welcomes Dr. Joseph Lehar as a Senior Vice President of Strategy & Business Development to Propel Platform With Strategic Partnerships newswire.com ... medicine to transform healthcare. Before his current activity advising ventures, small companies, and incubators, Joseph led cross-functional teams and drove scientific projects at J&J/Janssen (as VP of Data Science), Google/Verily, Novartis , and CombinatoRx. He is deeply committed to boosting the careers of those around him and is proud to serve on the board of WEST, a leading women's empowerment organization in Boston. Joseph brings an unusual ...
6/15/2021 Owkin Welcomes Dr. Joseph Lehar as a Senior Vice President of Strategy & Business Development to Propel Platform With Strategic Partnerships PR Newswire ... medicine to transform healthcare. Before his current activity advising ventures, small companies, and incubators, Joseph led cross-functional teams and drove scientific projects at J&J/Janssen (as VP of Data Science), Google/Verily, Novartis , and CombinatoRx. He is deeply committed to boosting the careers of those around him and is proud to serve on the board of WEST, a leading women's empowerment organization in Boston . Joseph brings an unusual ...
6/15/2021 Owkin Welcomes Dr. Joseph Lehar as a Senior Vice President of Strategy & Business Development to Propel Platform With Strategic Partnerships Yahoo News ... medicine to transform healthcare. Before his current activity advising ventures, small companies, and incubators, Joseph led cross-functional teams and drove scientific projects at J&J/Janssen (as VP of Data Science), Google/Verily, Novartis , and CombinatoRx. He is deeply committed to boosting the careers of those around him and is proud to serve on the board of WEST, a leading women's empowerment organization in Boston . Joseph brings an unusual ...
6/15/2021 Owkin Welcomes Dr. Joseph Lehar as a Senior Vice President of Strategy & Business Development to Propel Platform With Strategic Partnerships papernewsnetwork.com ... medicine to transform healthcare. Before his current activity advising ventures, small companies, and incubators, Joseph led cross-functional teams and drove scientific projects at J&J/Janssen (as VP of Data Science), Google/Verily, Novartis , and CombinatoRx. He is deeply committed to boosting the careers of those around him and is proud to serve on the board of WEST, a leading women’s empowerment organization in Boston . Joseph brings an ...
6/15/2021 Owkin Welcomes Dr. Joseph Lehar as a Senior Vice President of Strategy & Business Development to Propel Platform With Strategic Partnerships tncontentexchange.com ... medicine to transform healthcare. Before his current activity advising ventures, small companies, and incubators, Joseph led cross-functional teams and drove scientific projects at J&J/Janssen (as VP of Data Science), Google/Verily, Novartis , and CombinatoRx. He is deeply committed to boosting the careers of those around him and is proud to serve on the board of WEST, a leading women's empowerment organization in Boston . Joseph brings an unusual ...
6/15/2021 NEW YORK Latino News newyorklatinonews.com ... medicine to transform healthcare. Before his current activity advising ventures, small companies, and incubators, Joseph led cross-functional teams and drove scientific projects at J&J/Janssen (as VP of Data Science), Google/Verily, Novartis , and CombinatoRx. He is deeply committed to boosting the careers of those around him and is proud to serve on the board of WEST, a leading women's empowerment organization in Boston . Joseph brings an unusual ...
6/9/2021 Breast Cancer Therapeutics Market Share Growth, Size Value, Trends, Rigonal outlook by 2028 heraldkeeper.com ... U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.Global breast cancer therapeutics market share consists of several players including Teva Pharmaceutical Industries, Puma Biotechnology, GlaxoSmithKline, Roche Diagnostics, AstraZeneca, Novartis , Eli Lilly, Sanofi, Pfizer, and Eisai.The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report ...
6/9/2021 AHF Salutes Biden Administration for Ordering Drug Price Discounts southfloridagaynews.com ... and hospitals because they were using contract pharmacies."In its press release last week, Ged Kensela, the AHF spokesperson, lauded the U.S. Health Resources Services Administration for sending six letters informing AstraZeneca, Eli Lilly, Novartis , Novo Nordisk, Sanofi and United Therapeutics their practices were unacceptable. The letters advised the companies "that they are in direct violation of the statute establishing the 340B Drug Pricing Program."“Thousands of non-profit providers ...
6/9/2021 CALIFORNIA Latino News californialatinonews.com ... market is concentrated, and the degree of concentration will accelerate during the forecast period. AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA are some of the major market participants. The targeted therapeutic mechanism of action will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold ...
6/9/2021 Bi-Specific MAbS Global Market Report 2021: COVID 19 Growth And Change to 2030 Globe Newswire Bi-Specific MAbS Global Market Report 2021: COVID 19 Growth And Change to 2030 Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd. , Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc. , Bistro-Myers Squibb. June 09, 2021 05:18 ET ReportLinker Lyon, FRANCENew York, June 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report ...
6/9/2021 Latest News:: Global Cyclooxygenase 2 Inhibitor Market Size, Share, Growth, Trends, Insights and Restraints Analysis till 2026| Pfizer, Bayer, Novartis, Merck, Sabinsa sunrisenigeria.com Latest News:: Global Cyclooxygenase 2 Inhibitor Market Size, Share, Growth, Trends, Insights and Restraints Analysis till 2026 Pfizer, Bayer, Novartis, Merck, Sabinsa 3 hours ago reporthive“ Global Cyclooxygenase 2 Inhibitor Market Research Report estimates the size of the market for 2020 and projects its growth by 2026. It provides a detailed qualitative and quantitative analysis of the Global Cyclooxygenase 2 Inhibitor market. And collect useful data for this extensive ...
6/8/2021 ‘Next big wave’: Radiation drugs track and kill cancer cells tdtnews.com ... a division at the National Cancer Institute that helps develop such medicine.Results were released June 3 by the American Society of Clinical Oncology ahead of its annual meeting. The study was funded by Novartis , the drug’s maker, which plans to seek approvals in the United States and Europe later this year.When cancer is confined to the prostate, radiation can be beamed onto the body or implanted in ...
6/6/2021 STAT+: Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated STAT Attendees at the ASCO meeting in 2017, when it was held in Chicago and not virtual like this year. Courtesy ASCO/Scott MorganA Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells delayed tumor growth and extended survival in men with advanced disease, according to results of a late-stage clinical trial.Treatment with what Novartis calls radioligand therapy — thankfully, because its scientific ...
6/1/2021 Century Therapeutics Adds Respected Biotech Executives to Board of Directors PR Newswire ... stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell , M.D., as new Independent Directors.A former Executive Vice President at Gilead Sciences and Novartis Pharmaceuticals, Dr. Riva has a reputation for leading global research and development in the biopharma sector as well as developing and registering several therapeutic compounds in oncology. Dr. Blackwell is an expert oncologist with 24 ...
6/1/2021 PENNSYLVANIA Latino News pennsylvanialatinonews.com ... stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell , M.D., as new Independent Directors.A former Executive Vice President at Gilead Sciences and Novartis Pharmaceuticals, Dr. Riva has a reputation for leading global research and development in the biopharma sector as well as developing and registering several therapeutic compounds in oncology. Dr. Blackwell is an expert oncologist with 24 ...
6/1/2021 Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis drugs.com Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ -- Novartis , a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy1. This ...
5/29/2021 Quinolones Market to Eyewitness Massive Growth by 2028: Bayer, Sanofi, Johnson & Johnson, Merck, LG Corporation ksusentinel.com ... major factors, cost Structure and regulatory factors. At present, the market is developing its presence and some of the key players from the complete study are Bayer, Sanofi, Johnson & Johnson, Merck, LG Corporation, Allergan, Novartis The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using ...
5/28/2021 Leading Players in the Global Topical Drug Delivery Market - Future Growth Prospects emailwire.com Johnson & Johnson (US), Nestlé Skin Health (Switzerland), Novartis (Switzerland), Mylan (US), Bayer (Germany), Hisamitsu Pharmaceutical (Japan), and GlaxoSmithKline (UK), are the leading players. ( EMAILWIRE.COM , May 28, 2021 ) The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period. The high prevalence of skin and soft tissue infections, the increasing prevalence of eye ...
5/27/2021 Novartis, Molecular Partners kick off global trial for COVID-19 drug, with 2 data expected this summer FierceBiotech ... with COVID-19 infection confirmed by an antigen test and who experience at least two pre-determined mild to moderate symptoms within a week of their diagnosis.RELATED: After Mesoblast COVID-19 drug flop, Novartis tries again with Molecular PartnersThe companies expect the phase 2 part to read out in August this year, at which point the partners will move into phase 3. If all goes to plan and ...
5/27/2021 Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 Globe Newswire EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization - The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 - Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 - DARPin® antiviral therapeutic candidates that are undergoing ...